NurExone Biologic Inc. Announces First Quarter 2025 Financial Results and Provides Corporate Update
Globenewswire·2025-05-27 12:59
TORONTO and HAIFA, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is pleased to announce its financial results for the first quarter ended March 31, 2025, and provides a corporate update on its recent activities and upcoming milestones. The Company’s full set of unaudited condensed interim consolidated fina ...